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Introduction: Cervical cancer is one of the most common cancers diagnosed in women worldwide. Mamma-
lian cells are constantly exposed to a wide variety of genotoxic agents from both endogenous and exogenous
sources. The RAD51 protein is required for meiotic and mitotic recombination and plays a central role in
homology-dependent recombinational repair of double-strand breaks (DSBs). Given the functional relevance
of the DNA repair system on carcinogenesis, potential associations between genetic polymorphisms of DNA
repair genes, cancer risk and response to therapy have been intensively evaluated. This is the ﬁrst study eval-
uating the role of the RAD51 G172T genetic variants in cancer prognosis and clinical outcome of cervical can-
cer patients.
Material and methods: We analyzed RAD51 G172T polymorphism genotypes in cervical cancer patients who
underwent a platinum-based chemotherapy in combination with radiotherapy. Genotyping was performed
by Taqman™ Allelic Discrimination methodology.
Results and discussion: Concerning the overall survival rates found using Kaplan–Meier method and Log Rank
Test, we observed that the mean survival rates were statistically different according to the patients RAD51 ge-
notypes. The group of patients carrying the T allele present a higher mean survival rate than the other pa-
tients (102.3 months vs. 86.4 months, P=0.020). Using the Cox regression analysis, we found an increased
overall survival time for T-carrier patients, when compared with GG genotype, with tumor stage, age and
presence of lymph nodes as covariates [hazard ratio (HR), 0.373; 95% CI, 0.181–0.770; P=0.008]. Among pa-
tients (n=193), RAD51 genotype frequency distributions were not under the inﬂuence of clinicopathologic
characteristics, namely, treatment response (P=0.508), recurrence (P=0.150) and tumor stage (P=0.250).
Conclusions: This is the ﬁrst study evaluating the role of the RAD51 G172T genetic variants in cancer prognosis
and clinical outcome of cervical cancer patients. Our results indicate an inﬂuence of the RAD51 genetic vari-
ants in overall survival of cervical cancer. Thereby, RAD51 G172T genotypes may provide additional prognos-
tic information in cervical cancer patients who underwent cisplatin-based chemotherapy in combination
with radiotherapy.© 2012 Elsevier B.V. All rights reserved.otherapy; HPV, Human papil-
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Cervical carcinoma is the third most common cancer in females,
following breast and colorectal cancer. Worldwide, approximately
500,000 new cases are diagnosed each year, with a higher rate of inci-
dence amongwomen of lower socioeconomic status, especially in devel-
oping countries (Parkin et al., 2005).
The treatment of cervical cancer has changed over time. Randomized
studies (Keys et al., 1999; Morris et al., 1999; Rose et al., 1999) showed
that a combined modality approach, including cisplatin with/without
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survival, progression-free survival and recurrence rates in patients
with locally advanced cervical cancer. The use of radiotherapy and
concurrent cisplatin-based chemotherapy has become the standard
treatment in locally advanced cervical cancer (Keys et al., 1999). Surgery
and radiation therapy are equally effective for early stage, small-volume
disease (Eifel et al., 1991), but for patients with inoperable cervical can-
cer, radiochemotherapy (RCT) is the preferred treatment.
Human papillomavirus (HPV) is a common sexually transmitted in-
fection and has been shown in epidemiological andmolecular studies to
be a necessary etiologic agent for cervical cancer (Medeiros et al., 2005;
Silva et al., 2011). In considering the factors responsible for the changes
seen in HPV and cervical cancer epidemiology, viral factors (increased
virulence and predominance of high-risk types), host factors (changes
in behavior and immunity), and changes in screening and diagnosis
were considered (Barnabas et al., 2006). In addition to HPV infection,
smoking is a consistent cofactor for carcinomaof the cervix across retro-
spective and prospective studies (Matos et al., 2005).
Mammalian cells are constantly exposed to a wide variety of geno-
toxic agents from both endogenous and exogenous sources. These mu-
tagens sources produce a wide range of DNA lesions as reactive oxygen
species, oxidized bases, bulky DNA adducts and DNA strand breaks
(Cavalieri et al., 2000; Johnson-Thompson and Guthrie, 2000). The re-
sponse of the cell to DNA damage and its ability to maintain genomic
stability by DNA repair are crucial for preventing cancer initiation and
progression (Synowiec et al., 2008).
Double-strand break (DSB) damage is the most injurious lesion ob-
served because it causes cell death or loss of genetic material. Homolo-
gous recombination (HR) and non-homologous end joining (NHEJ) are
two distinct mechanisms in the repair of double-strand break in mam-
malian cells (Jara et al., 2007). DNA repair pathways have a critical role
for maintaining genomic stability and suppressing mutations (Dixon
and Kopras, 2004).Table 1
Distribution of patient clinicopathologic characteristics.
Characteristic No. of patients
(N)
%
Age
Median, 48.00 193 100
Mean±SD, 49.24±11.21
ACO (oral anticonceptives)
Yes 79 40.9
No 78 40.4
No information 36 18.7
Smoking habits
Non-smoker 128 66.3
Smoker/ex-smoker 26 13.5
No information 39 20.2
Histology
Squamous 153 79.3
Adenocarcinoma 25 13.0
Adenosquamous 7 3.6
Others 8 4.1
Lymph nodes
Yes 9 4.7
No 184 95.3
Therapy response
Complete 142 73.6
Partial 32 16.6
Persistence/stable 10 5.2
Progression 6 3.1
No information 3 1.5
Recurrence
Yes 36 18.7
No 157 81.3
Stage
I 18 9.3
II 134 69.4
III 37 19.2
IV 4 2.1Human RAD51, a homologue of recA protein in Escherichia coli, is re-
quired for meiotic andmitotic recombination and plays a central role in
homology-dependent recombinational repair of DSBs (Poplawski et al.,
2006). In that process, it promotes strand invasion, polymerizing onto a
DNA end and mediating the transfer and annealing of the resulting nu-
cleoprotein ﬁlament to complementary homologous strand on the in-
tact (Kawabata et al., 2005; Thompson and Schild, 2001).
RAD51 gene is located at chromosome position 15q15.1 in humans
(Shinohara et al., 1993). It spans >39 kb, contains 10 exons and en-
codes a 339 amino acid protein. The ﬁrst exon and part of the second
exon of RAD51 are located at its 5′-untranslated region (5′-UTR),
which may regulate gene expression. RAD51 is highly polymorphic:
143 single nucleotide polymorphisms (SNPs) of RAD51 are known.
However, only a few SNPs are located in the coding regions of RAD51,
none of which has a minor allele frequency (MAF) >5%, suggesting
that is protein structure may be genetically conservative (Lu et al.,
2007).
A single nucleotide polymorphism in the 5′-UTR of the human gene,
resulting in a guanine–thymine (G–T) substitution at the 172 position
(the RAD51 G172T polymorphism, rs1801321), has been identiﬁed. This
polymorphism has been reported to be associated with altered gene
transcription (Hasselbach et al., 2005). However, no reported studies
have investigated the role of RAD51 SNPs in the etiology of cervical can-
cer. Given the functional relevance of the DNA repair system on carcino-
genesis, potential associations between genetic polymorphisms of DNA
repair genes, cancer risk and response to therapy have been intensively
evaluated (Hung et al., 2005).
The purpose of our study was to assess the effect of RAD51 G172T
polymorphism in treatment response in cervical cancer patients.
2. Materials and methods
2.1. Patients
We conducted a hospital-based study analyzing 193 Caucasian fe-
male individuals from the north region of Portugal with cervical can-
cer, admitted in the Portuguese Institute of Oncology, Porto, Portugal.
These patients were randomly selected among those submitted to a
chemotherapeutic protocol, between 2000 and 2008, that consisted
of platinum-based chemotherapy in combination with radiotherapy.
The median age at diagnosis was 48.00 years with a mean age of
49.24 years (standard deviation, SD=11.21). Patients' clinical charac-
teristics, obtained from medical records, are described in Table 1. The
tumor stage was evaluated according to the TNM system proposed by
the American Joint Committee on Cancer (AJCC) and the International
Federation of Gynaecology and Obstetrics (FIGO), and the assessment
of histology typewasbased the on systemof Bethesda classiﬁcation. Ge-
nomic DNA was extracted from peripheral blood samples by using
QIAmp DNA Blood Mini kit (QIAGEN), according to the manufacturer's
protocol. All samples were obtained with the informed consent of the
participants prior to their inclusion in the study, according to Helsinki
Declaration principles.
2.2. Genotyping of RAD51 G172T polymorphism
Candidate single-nucleotide polymorphism was selected from the
best evidence from published studies and through public databases
that provide information on the phenotypic risks.
The detection of the RAD51 G172T polymorphism (rs1801321) was
carried out essentially as previously described (Rollinson et al., 2007).
The genotyping was performed using Taqman™ Allelic Discrimi-
nation. Primer and probe sequences were as follows: forward
primer 5′-CGAGTAGAGAA-GTGGAGCGTAAGC-3′, reverse primer
5′-CCGCGCTCCGACTTCA-3′, T allele probe 5′-FAM-CGTGCCACt-
CCCGCGGG-3′, G allele probe 5′-VIC-CGTGCC-ACgCCCGCGGG-3′.
All allelic discrimination PCR reactions were carried out in 6 μl
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Fig. 1. Overall survival by Kaplan–Meier and Log Rank Test of cervical cancer patients,
according to RAD51 G172T genotypes.
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0.125 μl of 40x assay mix 2.375 μl of sterile H2O and 1 μl of geno-
mic DNA.
Ampliﬁcation of DNAwas carried out using the following ampliﬁca-
tion conditions: 95 °C for 10 min, followed by 45 cycles of 95 °C for 15 s
and 60 °C for 1 min. Data capture and analysis was carried thought the
ABI 7300 Real Time PCR System (Applied Biosystems) and the Sequence
Detection Systems software (Applied Biosystems version 1.2.3).
Quality control included the use of non template controls in all runs
and blind replicate genotype assessment on 10% of the samples.We ob-
served almost complete concordance among duplicates.
2.3. Statistical analysis
Analysis of data was performed using the computer software Sta-
tistical Package for Social Sciences (SPSS) for Windows (version 17.0).
Differences in proportions were evaluated by the χ2 test. The proba-
bilities of survival were calculated and the means life tables were
computed using the product-limit estimate of Kaplan–Meier method.
The curves were analyzed by the Log Rank (Mantel–Cox) test, a statis-
tical test equality of survival distributions. A level of Pb0.05 was con-
sidered statistically signiﬁcant. Survival duration was deﬁned as the
time between diagnosis and either time of death or time last clinical
evaluation of the patient. Cox regression models were used to adjust
for potential confounders with RAD51 genotypes ﬁtted as indicator
variables.
3. Results
We analyzed RAD51 G172T polymorphism genotypes using the
Taqman™ Allelic Discrimination methodology. The frequencies of GG,
GT, and TT genotypes were 0.32, 0.43, and 0.25, respectively.
There were no statistically signiﬁcant differences in genotype distri-
butions according to the patients clinicopathologic characteristics, name-
ly, treatment response (partial and complete; P=0.508), recurrence
(yes and no; P=0.150) and tumor stage (I/II and III/IV; P=0.250)
(Table 2).
Concerning the overall survival rates found using Kaplan–Meier
method and Log Rank Test (Fig. 1), we observed that the mean survival
rates were statistically different according to patients' genotypes. The
group of patients carrying the T allele present a higher mean survival
rate than the other patients (102.3 months vs. 86.4 months, P=0.020).
Thus, individualswith TT/GT genotypes showed ahigher overall survival,
conferring a better prognosis for T allele carrier patients.
Using a multivariate Cox regression model, we found an increased
overall survival time for T-carrier patients, when compared with GG ge-
notype,with tumor stage, age and presence of lymph nodes as covariates
[hazard ratio (HR), 0.373; 95% conﬁdence interval (95% CI), 0.181–0.770;
P=0.008] (Fig. 2).Table 2
Genotype frequencies of RAD51 G172T polymorphism in cervical cancer patients,
according to the clinical characteristics.
GG
N (%)
T carrier
N (%)
Pa
Therapy response
Not completeb 17 (8.9) 31 (16.3) 0.508
Complete response conﬁrmed 43 (22.6) 99 (52.1)
Recurrence
Yes 15 (7.8) 21 (10.9) 0.150
No 46 (23.8) 111 (57.5)
Stage
I/II 45 (23.3) 107 (55.4) 0.250
III/IV 16 (8.3) 25 (13.0)
a Chi square test.
b Parcial+persistence+progression+no response.4. Discussion
Molecular epidemiology studies have demonstrated that the SNPs
were found in nearly all human DNA repair genes that have been inves-
tigated so far (Mohrenweiser et al., 2003), and some of them were
shown modulate levels of DNA damage, individual DNA repair capacity
and cancer risk (Goode et al., 2002;Matullo et al., 2003). There is increas-
ing evidence that reduced DNA repair capacity resulting from genetic
polymorphisms of various DNA repair genes is associatedwith improved
survival with platinum-based chemotherapy (Gurubhagavatula et al.,
2004; Ryu et al., 2004; Zhou et al., 2004). Thus, DNA repair capacity is
considered both a barrier to carcinogenesis and a crucial molecular
pathway implicated in the resistance to cisplatin-based chemotherapy
(Kelland, 2007; Wei et al., 2000). Therefore, gene polymorphisms of
DNA repair factors are therefore obvious candidates for determinants
of repair capacity and chemotherapy efﬁcacy (Sancar, 1995). Moreover,
the functional variants caused by SNPs in genes encoding drug-
metabolizing enzymes, transporters, ion channels, drug receptors, cell
cycle proteins and DNA repair are known to be associated with individ-
ual variation in survival, drug responses, and toxicity (Henson et al.,
2006; Costa et al., 2008; Nogueira et al., 2010; Catarino et al., 2008;
Craveiro et al., 2012; Santos et al., 2006; Medeiros et al., 2003).
Faithful genome transmission requires the co-ordination of a net-
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Fig. 2. Cox regression analysis of overall survival adjusted with stage, age and presence
of lymph nodes as covariates, according to the RAD51 G172T polymorphism.
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2002). The RAD51 gene is an essential factor for homologous recombi-
nation and the repair of DNA DSBs, binding transiently to both single
stranded and double stranded DNA during the recombination reac-
tion. RAD51 has been found to be increased in expression in a wide
range of human tumors, most likely contributing to chemotherapeu-
tic resistance of these tumors (Klein, 2008). According to previous
studies in other tumor models, the study of RAD51 gene seems to be
important for the prediction of treatment response with chemother-
apeutic drugs (Connell et al., 2006). It remains unclear whether the
link of RAD51 expression to sensitivity to platinum agents may affects
the prognosis (Takenaka et al., 2007).
In previous studies, RAD51 expression was identiﬁed as an indepen-
dent predictor for tumor recurrence, as well as for tumor progression.
These data demonstrate RAD51 expression as a clinical signiﬁcant prog-
nosticmarker. Increased RAD51 protein levels could lead to uncontrolled
recombination, genome instability, prevention of apoptosis, cell cycle ar-
rest and increased resistance tumor to radiotherapy and chemotherapy.
Down-regulation of RAD51 protein by anti-sense oligonucleotides or
small molecules that sensitizes cells to DNA-damaging agents (Ohnishi
et al., 1998) may be a promising strategy for tumor therapy (Henning
and Sturzbecher, 2003).
Polymorphisms in UTR region have been shown to be important for
cell proliferation, differentiation, tumor suppression, and metastasis
suppression on several genes (Facher et al., 1997; Fan et al., 1996). For
this reason, RAD51 G172T polymorphism at the 5′-UTR region can
have an important role on protein expression and stability. As it is locat-
ed in the 5′-UTR region of the RAD51 gene, this genetic variation could
affect mRNA stability or translational efﬁciency, leading to altered poly-
peptide product levels and altering the function of the ﬁnal product —
the RAD51 protein (Hasselbach et al., 2005; Lu et al., 2007).
Some studies showed an association between the RAD51 G172T poly-
morphismand risk of breast (Kuschel et al., 2002; Lee et al., 2005), epithe-
lial ovarian cancers (Auranen et al., 2005), and squamous cell carcinoma
of the head and neck (Lu et al., 2007). However, none of these studies in-
vestigated the role of this polymorphism in the therapy response as a
prognostic factor to cervical cancer patients. In this study, our results indi-
cate an inﬂuence of the RAD51 genetic variants in overall survival of cer-
vical cancer. Thereby, we suggest that the RAD51 G172T genotypes may
provide additional prognostic information in cervical cancer patients
who underwent cisplatin-based chemotherapy in combination with ra-
diotherapy. Our results indicate that individuals carrying the T allele
present an overall survival of approximately 102 months after chemo-
therapy, compared with 86 months for individuals carrying the GG
genotype.
The functional consequences of RAD51 polymorphisms are not fully
understood. Although future functional studies are needed to clarify
this question, we hypothesized that the RAD51 variant allelesmay orig-
inate a lower activity of RAD51 promoter (Nogueira et al., 2010). Thus,
individuals carrying the RAD51 172TT genotypemay have a lower cellu-
lar capacity for DSB repair or present a greater sensitivity to chemother-
apeutic agents than carriers of other genotypes, supporting our
observation that the RAD51 172TT genotype has a protective effect on
clinical outcome of cervical cancer patients.
The positive effect in treatment response that we observe for RAD51
G172T polymorphism suggests that it may be associated with decreas-
ing RAD51 expression levels in tumor cells, originating sensitized
tumor cells with lower cellular capacity for damage repair and most
sensitizes for chemotherapeutic agents, thus increased the efﬁcacy of
chemotherapy and giving a better prognosis for cervical cancer patients.
Although some known regulatory elements are associatedwith 5′-UTRs
(Gray and Wickens, 1998; van der Velden and Thomas, 1999), it is not
clear how172T polymorphismmight affect gene function. Further stud-
ies may clarify these putative functional implications.
To the best of our knowledge, this is the ﬁrst study evaluating the
role of theRAD51G172T genetic variants in cancer prognosis and clinicaloutcome of cervical cancer patients suggesting a role as a molecular
marker for predicting the clinical outcome of cervical cancer patients.
Patient pharmacogenomic proﬁling is being used to predict whether the
selected chemotherapywill be really effective and tolerable to the patient.
Thus, DNA repair genotypes may be add to the pharmacogenomic strate-
gy to elucidate how an adversely or favorably response to chemotherapy
outcome may occur.
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